Table 6 Sensitivity analysis: total medical costs per patient (euros)
PLD | Topotecan | Difference | |
|---|---|---|---|
(a) Changing length of hospitalisation and number of visits | |||
Total cost drug+administration | 8647.70 | 8519.94 | 127.76 |
Total cost adverse events | 1087.04 | 2657.65 | −1570.61 |
Total cost | 9734.74 | 11 177.59 | −1442.85 |
(b) Equalising number of cycles | |||
Total cost drug+administration | 8647.70 | 7935.36 | 712.34 |
Total cost adverse events | 967.02 | 3304.75 | −2337.73 |
Total cost | 9614.72 | 11 240.11 | −1625.39 |
(c) Cost of antiemetics required for topotecan=0 | |||
Total cost drug+administration | 8647.70 | 7896.13 | 751.57 |
Total cost adverse events | 967.02 | 3304.75 | −2337.73 |
Total cost | 9614.72 | 11 200.88 | −1586.16 |
(d) Application of a, b and c (above) | |||
Total cost drug+administration | 8647.70 | 7397.08 | 1250.62 |
Total cost adverse events | 1087.04 | 2657.65 | −1570.61 |
Total cost | 9734.74 | 10 054.73 | −319.99 |
(e) Lower doses of PLD and topotecan | |||
Total cost drug+administration | 7090.61 | 7810.50 | −719.89 |
Total cost adverse events | 967.02 | 3304.75 | −2337.73 |
Total cost | 8057.63 | 11 115.25 | −3057.62 |
